Clinically, prostate cancer is typically identified through methods such as digital rectal examination, prostate-specific antigen (PSA) blood test, transrectal ultrasound (TRUS)-guided biopsy, or magnetic resonance imaging (MRI) [3]. This evidence concerns the gene KLK3 and prostate cancer.